Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide

The study, involving 445 subjects (268 males and 177 females), explored the efficacy of proxalutamide, a potent non-steroidal antiandrogen, in improving inflammatory, immunologic, and thrombogenic responses in mild-to-moderate COVID-19 patients. The results showed that proxalutamide led to significant improvements in various markers. Neutrophils were lower, and lymphocytes and eosinophils were higher in the proxalutamide group. Platelets, testosterone levels in both males and females, and estradiol levels in females were also higher in the proxalutamide group. Additionally, ferritin, fibrinogen, D-dimer, ultrasensitive C-reactive protein levels, and 1-hour erythrocyte sedimentation rate were lower in the proxalutamide group. Oxygen saturation was also higher in the proxalutamide group. These improvements may support the reduction of hospitalization rate observed in both females and males with COVID-19 using proxalutamide, compared to standard of care.